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Key Points
• Inhibitors of human Syk
kinase suppress parasite
egress.
• Syk inhibitors prevent the
tyrosine phosphorylation of
band 3 in P falciparum
parasitized red blood cells,
reducing the release of
microparticles.
Band 3 (also known as the anion exchanger, SLCA1, AE1) constitutes the major
attachment site of the spectrin-based cytoskeleton to the erythrocyte’s lipid bilayer and
thereby contributes critically to the stability of the red cell membrane. During the
intraerythrocytic stage of Plasmodium falciparum’s lifecycle, band 3 becomes tyrosine
phosphorylated in response to oxidative stress, leading to a decrease in its affinity for the
spectrin/actin cytoskeleton and causing global membrane destabilization. Because this
membrane weakening is hypothesized to facilitate parasite egress and the consequent
disseminationof releasedmerozoites throughout thebloodstream,wedecided toexplore
which tyrosine kinase inhibitors might block the kinase-induced membrane destabiliza-
tion. We demonstrate here that multiple Syk kinase inhibitors both prevent parasite-
induced band 3 tyrosine phosphorylation and inhibit parasite-promoted membrane
destabilization. We also show that the same Syk kinase inhibitors suppress merozoite
egress near the end of the parasite’s intraerythrocytic lifecycle. Because the entrapped
merozoites die when prevented from escaping their host erythrocytes and because some Syk inhibitors have displayed long-term
safety in human clinical trials, we suggest Syk kinase inhibitors constitute a promising class of antimalarial drugs that can suppress
parasitemia by inhibiting a host target that cannot be mutated by the parasite to evolve drug resistance. (Blood. 2017;130(8):1031-1040)
Introduction
The humanmalaria parasite, Plasmodium falciparum, currently infects
.200 million people annually, causing;500 000 deaths per year and
imposing considerable morbidity on the surviving population.1,2
Because strains of P falciparum are rapidly emerging that are resistant
to all known antimalarial drugs, including artemisinin, quinine,
chloroquine, piperaquine, and meﬂoquine and their derivatives,
considerable emphasis is now being focused on development of new
therapies with novel mechanisms of action.2-6 Although reports of
promising new antimalarials are now appearing in the literature,7-15 that
vast majority of these novel drug candidates target parasite-encoded
proteins/pathways, leaving the opportunity open for adventitious
parasites to mutate resistance to the new therapeutics. As noted by
others, the ideal solution to this problem would emerge if new anti-
malarials could be developed that would function by inhibiting a host-
encoded protein/pathway that the parasitemust coopt in order to survive
and proliferate.8,16 Following this guidance, the goal of this workwas to
identify an erythrocyte-encoded enzyme whose inhibition would
prevent theparasite’s propagation and thereby terminate theparasitemia.
Inour search for such a critical erythrocyte enzyme,weundertook to
identify the parasite-induced changes in erythrocytemembrane biology
that might require the integral participation of human red blood cell
(RBC) components.7,17-25 Although the Plasmodium species is well
known to export hundreds of proteins into the erythrocyte compart-
ment, including lipid kinases, multiple structural proteins, and a
tyrosine phosphatase-like enzyme that must be activated to facilitate
parasite invasion,26-29 we noted that the steady increase in tyrosine
phosphorylation of erythrocyte membrane band 3 during parasite
maturation would likely involve an erythrocyte tyrosine kinase.19,20,30
This line of investigation was further encouraged by the observation
that tyrosine phosphorylation of band 3 had been previously shown to
cause rupture of the band 3–ankyrin bridge connecting the erythrocyte
membrane to its spectrin/actin cytoskeleton, and rupture of this bridge
promotes severe membrane destabilization, vesiculation, and fragmen-
tation.31 Considering these observations together,we hypothesized that
parasite-triggered activation of some RBC tyrosine kinasemight cause
the membrane weakening that enables egress of the parasite from its
RBC host and thereby facilitate propagation of the parasitemia. To test
this hypothesis, we elected to examine whether any RBC tyrosine
kinase inhibitors might effectively prevent both RBC membrane
weakening and the consequent escape of mature merozoites from their
Submitted 4 November 2016; accepted 5 June 2017. Prepublished online as
Blood First Edition paper, 20 June 2017; DOI 10.1182/blood-2016-11-748053.
The online version of this article contains a data supplement.
There is an Inside Blood Commentary on this article in this issue.
The publication costs of this article were defrayed in part by page charge
payment. Therefore, and solely to indicate this fact, this article is hereby
marked “advertisement” in accordance with 18 USC section 1734.
© 2017 by The American Society of Hematology
BLOOD, 24 AUGUST 2017 x VOLUME 130, NUMBER 8 1031
For personal use only.on September 22, 2017. by guest  www.bloodjournal.orgFrom 
infected host erythrocytes. In this paper, we demonstrate that multiple
inhibitors of erythrocyte Syk tyrosine kinase block the customary
erythrocyte membrane vesiculation that occurs during parasite
maturation. We further show that these same inhibitors suppress
parasite egress at the end of its lifecycle and thereby prevent spread
of the merozoites in cultures of fresh human erythrocytes.
Materials and methods
Unless otherwise stated, all materials were obtained from Sigma-Aldrich
(St. Louis, MO).
Cultivation of P falciparum–infected RBCs
Freshly drawn blood (Rh1) from healthy adults of both sexes was used. Patients
provided written, informed consent before entering the study. The study was
conducted in accordance with Good Clinical Practice guidelines and the
DeclarationofHelsinki andwasapprovedbyHueUniversityEthicsCommittee.
Blood anticoagulated with heparin was stored in citrate-phosphate-dextrose
with adenine prior to its use. RBCswere separated from plasma and leukocytes
by 3 washings in RPMI 1640 medium. P falciparum laboratory strains Palo
Alto, it-G, and Dd2 (mycoplasma-free) and fresh isolates from the Quang Tri
province of Vietnam were cultivated in RPMI 1640 medium containing N-2-
hydroxyethylpiperazine-N9-2-ethanesulfonic acid, supplemented with 20 mM
glucose, 2 mM glutamine, 0.025 mM adenine, and 32 mg/L gentamycin at 2%
hematocrit.32,33 Parasite cultures were synchronized as described by Lambros
and Vanderberg.34 For the assessment of half-maximal drug concentration for
inhibition of malaria survival (IC50) values,
35 synchronized P falciparum–
infected RBCs cultures were used at ring stage (14 to 18 hours postinfection) or
trophozoite stage (34 hours to 38 hours), at a parasitemia of ;10%. Where
indicated, cultures were treated with the Syk inhibitors: Syk inhibitor II, Syk
inhibitor IV (from now on abbreviated as SYK II and SYK IV, respectively),
and R406 (Calbiochem, Darmstadt, Germany), at concentrations ranging from
0.05 to 5 mM. Untreated controls were cultured in parallel under the same
conditions and processed identically. To assess both total parasitemia and
infected cell morphology, thin smears were prepared from cultures, collected at
the indicated times, and stained with Diff-Quick stain (Medion Diagnostics)
with at least 1000 cells being examined for each condition. For the studies
on parasitized RBC (pRBC) membranes, parasites were cultured at high
parasitemias (;50%) until the ring stage and used to prepare the RBC
membranes. Cultures were then diluted with washed RBCs to bring the total
parasitemia to ;10%. Trophozoites and schizonts pRBCs were separated by
Percoll gradient and then diluted to 50% parasitemia with washed RBCs as
previously described.34
Membrane preparation and western blotting
Standard hypotonicmembranes from both uninfected andmalaria-infected RBC
were prepared at 4°C in 1.5 mL hemolysis buffer (5 mmol/L sodium phosphate,
1 mmol/L EDTA, pH 8.0) containing protease and phosphatase inhibitor
cocktails.36 Parasitemia was at 50%, as described above. To minimize handling
artifacts, the preparation of hypotonic membranes, including twice-repeated
2-minute washing steps, was performed in ,10 minutes. The preparations
were frozen for storage at 280°C until use. Membrane protein content was
quantiﬁed using the DC Protein assay (Bio-Rad, Hercules, CA).
Membranes from both infected and uninfected RBCs were solubilized
in Laemmli buffer,37 and proteins were separated on 8% polyacrylamide.
Nitrocellulose membranes were probed with mouse anti-band 3, mouse anti-
phosphotyrosine, or rabbit anti-Syk (Cell Signaling Technology, Inc) diluted to
1:1000 as described previously.38 Quantitative densitometry analysis was
performed using Odyssey V3.0 software.
Analysis of microparticles in P falciparum–infected RBC cultures.
Microparticles (MPs) collected by centrifugation ofP falciparum–infected RBC
cultures were quantitated in the presence or absence of R406 performed using a
FACSCalibur ﬂow cytometer (BectonDickinson Biosciences, San Jose, CA) as
previously described.39
Hemoglobin release quantiﬁcation. Following centrifugation at 1000g,
hemoglobin concentration was measured in the culture supernatant as
described.40,41 To pellet theMPs, the supernatant was further centrifuged at
100 000g for 3 hours at 4°C.39
Release of merozoites from their host red cell. Merozoite egress from
schizonts was quantiﬁed by ﬂow cytometry. Aliquots from a synchronized
parasite culture were taken before, during, and after reinfection and stained with
ethidium bromide (EtBr) at 5 mg/mL (ﬁnal concentration) for 20 minutes. This
staining allows distinguishing schizont from merozoite during ﬂow cytometry
based on their physical properties forward (FSC) and side (SSC) light scattering
and EtBr staining intensity at 564 to 606 nm with excitation at 488 nm, using a
FACSCalibur ﬂow cytometer (BD Biosciences, Sunnyvale, CA) and CellQuest
software(BDBiosciences).CytoCountbeads(DAKO,Glostrup,Denmark)wereused
ascontrol.Todeterminewhether themerozoites that remained trappedinside theirhost
RBCs membrane were still viable, we applied a moderate shear stress to mature
schizonts, passing them20 times through a sterile BDultraﬁne needle insulin syringe,
30 G312.7 mm, to disrupt the host cell membrane and to release the merozoites.
P falciparum DNA extraction and quantiﬁcation by quantitative
polymerase chain reaction. Ten microliters of P falciparum culture, 2% of
hematocrit, incubated in the presence or absence of SYK II, SYK IV, or R406,
was spotted onto ﬁlter paper and dried at room temperature (RT) for 20 minutes
or stored at 220°C until use. Spots were then transferred into a sterile
microcentrifuge tube, and DNA extraction was performed according to
manufacturer-suggested procedures (Nurex Srl, Italy). DNA ampliﬁcation was
conducted using primers and probe for the 18rRNAgene ofP falciparum adapted
from Kamau et al.42 Ampliﬁcation and detection were achieved using CFX96
Touch Real-Time PCRDetection System (Bio-Rad). Parasites were counted by a
standard curve obtained from serial dilutions of parasites counted bymicroscopy.
Quantiﬁcation of hemozoin generation. Ring-stage infected RBCs
(5-10 hours postinfection) were enriched from synchronized cultures to.95%
parasitemia using a 90% Percoll-mannitol cushion.43 Parasites were supple-
mentedwith 1 or 5mMR406or kept untreated as controls under standard culture
conditions for 38 hours. Then, parasites (43-48 hours postinfection) were
hypotonically lysed and washed in excess of lysis buffer (10 mM phosphate
buffer, pH 8.0). Sedimented hemozoin was solubilized in 0.1 N NaOH/0.05%
Triton X-100 (vol/vol) and quantiﬁed by heme-dependent luminol-enhanced
luminescence as described.44
IC50 measurement. To calculate the IC50, we used ICEstimator software,
1.2 version. The program estimates IC50 through nonlinear regression using a
standard function of the R software.35
Fluorescence and DIC microscopy. To stain merozoites and erythro-
cytes membrane, cells were harvested from a synchronized culture at 42 to
48 hours postinfection, washed, and incubated with the nuclear stain 49,6-
diamidino-2-phenylindole (300 nM) for 1 to 5 minutes at RT and with
phycoerythrin-conjugated monoclonal mouse anti-glycophorin A antibody
(DAKO; 1:50 ﬁnal dilution) for 30 minutes at RT. Analysis of ﬂuorescence
was performedbyﬂuorescencemicroscopy (LeicaMicrosystems) inwet smears.
Fluorescent images were acquired with a ﬂuorescence microscope (Leica
DR IRB; Leica Microsystems, Germany) equipped with a Leica DFC 420C
camera, a 1003oil planar apochromatic objective, and version 3.3.1 of the Leica
DFC image software (Leica Microsystems).
Synchronized P falciparum (Palo Alto) cultures at 1.5% parasitemia and
2% hematocrit were treated at 12 hpi with 5 mM R406 or DMSO for controls.
Starting at 44 hpi, aliquots of cultures were removed every 2 to 4 hours and
diluted in warm complete media for monitoring of egress by differential
interference contrast (DIC)microscopy. For imaging, sampleswere injected into
chambers (HybriWell HBW20; Grace Bio-Labs, Bend, OR) and then sealed just
prior to analysis in a 37°C heated chamber. DIC microscopy was performed
using a confocal microscope (Nikon A1R MP Confocal) with a 1003 oil
objective.Untreated and treated infected erythrocyteswith either SYKII orR406
weremonitored throughout the timeframeofuntreatedparasite egress. In total, 10
egress events of untreated cultures were recorded, whereas 10 defective egress
events for either SYK II or R406 treated cultures were characterized.
Scanning electron microscopy. Asexual late trophozoites untreated or
treated with R406 (2.5 mM and 5mM) were processed for scanning electron
microscopy (SEM) according to Tiburcio et al.45 All samples were ﬁxed with
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2.5% glutaraldehyde in 0.1 M sodium cacodylate buffer (pH 7.4) overnight at
4°C.Then, parasiteswere let to adhere on poly-lysine–coated glass coverslips for
4 hours, washed in cacodylate buffer, and postﬁxed with 1% OsO4 in 0.1 M
sodium cacodylate buffer for an additional 1 hour at RT. Samples were then
washedanddehydrated throughagraded seriesof ethanol solutions (30%to100%
ethanol), critical point dried and gold sputtered (thickness 30 nm), and examined
by a ﬁeld emission gun (INSPECT F, FEI) scanning electron microscope.
Results
Effects of Syk inhibition on phosphorylation and depletion of
band 3 in parasitized erythrocytes
As shown in Figure 1A, the levels of band 3 tyrosine phosphorylation
are very low in uninfected RBCs but increase progressively during
P falciparum development through its ring and trophozoite stages
before eventually declining at the schizont stage (Figure 1A). A Syk-
speciﬁc inhibitor (R406) causes a substantial decrease of band 3
phosphorylation during all stages of pRBC development. In parallel to
band 3phosphorylation, the rate ofMP released frompRBCsdisplays a
maximum at the trophozoite stage and a subsequent decrease at the
schizont stage (Figure 1B). The insert in Figure 1B shows an anti-Syk
western blot performed on isolatedMPs; it should be noticed that MPs
contain Syk and that the amount of Syk is proportional to the rate of
band 3 phosphorylation observed in Figure 1A. Importantly, R406
causes a reduction inMP release, but has no effect on the bindingof Syk
to the membranes. This observation is in accordance with previous
results.38,39 To evaluate if Syk inhibitors also cause a decrease in
hemolysis, we measured the amount of hemoglobin released into the
culture medium at the trophozoite stage (;36 hours postinfection)
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Figure 1. Abrogation of the P falciparum–induced erythrocyte membrane modifications by SYK inhibitors at different P falciparum lifecycle stages. Synchronized
P falciparum cultures were supplemented with SYK inhibitor R406 (1.0 mM) at ring stage (24 hours after invasion). (A) Band 3 tyrosine phosphorylation levels are expressed
as percentages of band 3 maximal phosphorylation measured at trophozoite stage and were normalized by the content of band 3 at each stage (% phosphorylation). The
insert shows a representative western blot of tyrosine phosphorylated band 3 in the absence of inhibitors in uninfected RBCs (U); ring-infected RBCs (R); trophozoite-infected
RBCs (T); and schizont-infected RBCs (S). (B) Number of MPs released from control and R406-treated cells. Values are expressed as a percentage of the maximal number of
released MPs measured at trophozoite stage (% Released MPs). The insert shows a representative anti-Syk western blot of MPs released at different stages (U, R, T, S). (C)
Band 3 content measured in control and R406-treated cells. Values are expressed as percentage of the band 3 measured at different stages using uninfected cells as
reference (% band 3). The insert shows a representative western blot of band 3 at different stages (U, R, T, S). (D) Membrane-bound Syk measured in control and R406-
treated cells. Values are expressed as a percentage of the maximal levels of bound Syk measured at trophozoite stage (% Syk). The insert shows a representative western
blot of Syk at different stages (U, R, T, S). Data are the average of 6 independent experiments 6 standard deviation (SD). Nitrocellulose membranes were stained with rabbit
anti-Syk (Cell Signaling Technology, Inc., CA) diluted to 1:1000, and with goat anti-rabbit IRDye 800CW (LI-COR), diluted to 1:50 000. Quantitative densitometry analysis was
performed using Odyssey V3.0 software. Photomicrographs were acquired using Odyssey from LI-COR, setting 300dpi as definition.
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and then ultracentrifuged the culture medium to assess whether
the hemoglobin might be encapsulated in MPs or free in the medium.
In accordance with the decreased release of MPs in treated cultures,
we observed a 54% decline in the amount of released hemoglobin in
the treated samples. Importantly, in both the control and the treated
cultures,.80% of the hemoglobin present in the supernatant was sed-
imentable by ultracentrifugation, indicating that it is contained within
the MPs.
Consistentwith the fact that band 3 comprises amajor constituent of
RBC MPs,7,39 we observed a progressive depletion of band 3 from
pRBCs during parasite maturation, declining to ;20% of the initial
content at the schizont stage (Figure 1C). It should be noticed that band
3 depletion will likely amplify the membrane destabilization triggered
by band 3 phosphorylation.31 Syk binding to oxidized band 3 and its
subsequent translocation to the membrane has been shown to follow
its activation.36 Figure 1D shows that Syk binding to theRBCmembrane
increases with parasite development, showing a dramatic drop at the
schizont stage. The decrease inmembrane-bound Syk at the schizont
stage may be explained by the progressive loss of both band 3 and
Syk (Figure 1C-D) during the release of MPs (Figure 1B-C).
Similarly, the observed depletion of Syk from the host cell
membrane may also account for the drop in band 3 phosphorylation
observed at the schizont stage (Figure 1A), but additional mechanisms
such as profound structural andmetabolic changes occurring during the
last phases of the parasite development could also explain the decrease
of band 3 phosphorylation observed in schizont-infected RBCs.46 To
conﬁrm that above effects of R406 indeed do derive from their
inhibition of RBC Syk, we then tested the effect of other Syk-speciﬁc
inhibitors (R406, Syk II, and Syk IV) on band 3 phosphorylation. Impor-
tantly, they all inhibited parasite-induced band 3 tyrosine phosphor-
ylation,MP release, and band 3 depletion induced byP falciparum to
a similar extent. In Figure 1, we show the effects of R406 as a
representative compound. Taken together, these results show that Syk
inhibitors efﬁciently suppress band 3 phosphorylation and the consequent
MPs release from the host cell membrane. Because of their action, Syk
inhibitors are expected to substantially reduce the host cell membrane
weakening occurring at the end of parasite development.
Effect of Syk inhibition on the parasite egress
Because the predominant effect of Syk inhibitors on pRBC de-
velopment occurs during the last stages of parasite maturation, we
hypothesized that they may limit the destabilization of the host cell
membrane required for the egress of the mature merozoites. To clarify
this issue, the accumulation of merozoite aggregates was consistently
observed in Syk inhibitor–treated cultures. Healthy merozoites had
egressed from untreated pRBCs, suggesting as a consequence that
degradative processes begin soon after merozoites are blocked in their
attempt to escape their host RBCs (Figure 2A). The most striking
morphological alteration observed in ﬁxed blood smears of parasite
culture, in comparison with control cultures, was the presence of
merozoite aggregates. Thus, staining of R406-treated parasite cultures
with anti–glycophorin A at the normal time of merozoite egress and
afterward revealed that merozoites are entrapped by residual RBC
membrane, as suggested by the glycophorin-containing membranous
structures colocalized with the 49,6-diamidino-2-phenylindole–
staining merozoites. Untreated control cultures, however, never
showed colocalization of merozoites and RBC membranes (see
supplemental Figure 1, available on the Blood Web site).
As Syk inhibition appears to affect host cell membrane changes
occurring at the end of the parasitematuration,we investigated its effect
on the formation of knobs. Figure 2B shows the results obtained by
SEM in pRBCs treated with R406 at the concentrations of 2.5mMand
5 mM. SEM analysis clearly shows that knobs are still formed on the
surface pRBCs treated by R406.
DIC microscopy recording of living P falciparum cultures also
revealed that Syk inhibitors quantitatively prevented merozoite egress
from pRBCs. A representative egress of untreated and a failed egress
in R406 (5 mM) treated pRBC is shown in the supplemental videos.
Those observations were further substantiated by the lower number of
countable merozoites released from isolated schizonts treated with
relatively low concentrations of R406 (1.0 mM) during the course of
2 hours of culture (Table 1).
To determine whether the merozoites that are trapped in Syk
inhibitor–treated pRBCs are still viable, we applied a moderate shear
stress to mature schizonts using a standard method to disrupt the host
Control
Control
R406 (1.0 µM)
R406 (2.5 µM) R406 (5 µM)
A
B
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5µm 5µm 5µm
ii iii
SCHIZOGONY
Figure 2. Morphological changes and knobs for-
mation in late maturation stages induced by Syk
inhibitors. Representative pictures of parasites at 48
hours postinfection in control and in R406-treated
cultures selected (A) from Diff-Quik fix stained thin
blood films and (B) representative picture of asexual
late trophozoite (i) untreated or treated with R406
(ii) 2.5 mΜ and (iii) 5 mΜ obtained by SEM.
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cell membrane and to release the merozoites. Following shear stress,
R406-treated cells were challenged with fresh RBCs to assess their
capability to infect theseRBCs (Table 1). Shear stress treatment of schiz-
onts promoted a measurable improvement in both the egress rate and
the infection rate, suggesting that many of the merozoites that be-
come entrapped within the inhibitor-treated pRBCs are still viable,
but incapable to egress. With higher concentrations (2.5mM) of R406,
the effect of shear stress on the infection rates markedly decreased
(Table 1), suggesting a directly toxic effect of higher amounts of
Syk inhibitors on the parasites. All of these experiments were also
performed using SYK II and SYK IV with results appearing
indistinguishable from the results obtained with R406.
Comprehensively, those results indicate that Syk inhibition affects
the egress phase due to their entrapment in residual RBC membranes,
although high concentrations of inhibitors can also hinder the
production of viable merozoites.
Effect of Syk inhibition on the parasite growth
To further investigate the action of Syk inhibitors on P falciparum
cultures, we measured their activity at different concentrations, at
different durations of treatment, on different parasite stages, and in
different strains.
In a ﬁrst set of experiments, parasitemia was monitored through
2 parasite cycles in the presence of different concentrations of R406
as representative Syk inhibitor, R406 was added 14 to 20 hours
postinfection (Figure 3). At low concentrations,1mM,we observed a
modest decrease in parasitemia during the ﬁrst cycle of growth and a
substantial decrease in parasitemiaduring the secondcycle (Figure 3A).
This phenomenonwas conﬁrmed by amodest, nonsigniﬁcant decrease
in the number of merozoites per mature schizont at the end of the ﬁrst
cycle of growth (Figure 3B), in DNA synthesis (Figure 3C) and also in
hemozoin formation (Figure 3D). At higher concentrations of R406,
a reduction of parasitemia was also apparent during the ﬁrst cycle of
Table 1. Infection and the egress rates of mature schizont isolated from cultures treated with R406 (1.0 and 2.5 mM)
Control [R406] (1 mM) [R406] (2.5 mM)
No shear stress Shear stress No shear stress Shear stress No shear stress Shear Stress
Infection rate 3.48 6 0.96 4.24 6 1.21 0.63 6 0.25 2.6 6 0.83 0.13 6 0.06 0.30 6 0.39
Egress rate 6.60 6 2.41 9.37 6 3.10 1.12 6 0.84 3.9 6 1.11 0.27 6 0.48 1.09 6 1.16
A portion of the schizonts were subjected to a rapid shear stress treatment to test its effect on the infection and egress rates. Results are the mean of 3 independent
experiments (6 SD) and expressed as number of released merozoites (egress rate) or number of infected RBC (infection rate) per each schizont present in the culture (no
shear stress/shear stress).
Infection rate, RBC infected per schizont; egress rate, merozoites released per schizont.
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Figure 3. Effect of Syk inhibitors on P falciparum intraerythrocytic growth cycle. (A) Parasitemia during the course of 2 growth cycles; R406 was added at 14 to
20 hours postinfection. (B) Number of merozoites per schizont measured at 48 hours postinfection. Data are the average of 7 experiments 6 SD. (C) DNA synthetic activity
measured at 42 to 48 hours postinfection using the untreated cells as a reference (% DNA synthesis). (D) The amount of hemozoin produced by the parasite during maturation
from ring to late trophozoite/schizont stage in the infected RBCs in the presence of R406 and in untreated parasites. Hemozoin was quantified in terms of heme content and is
expressed as mean hemozoin-heme per infected RBCs. Data are the average 6 SD of 4 independent experiments. * Significant differences to untreated control parasites at
P , .05.
BLOOD, 24 AUGUST 2017 x VOLUME 130, NUMBER 8 Syk INHIBITORS SUPPRESS P FALCIPARUM EGRESS 1035
For personal use only.on September 22, 2017. by guest  www.bloodjournal.orgFrom 
growth, and a signiﬁcant reduction of DNA, hemozoin synthesis, and
merozoite production was observed (Figure 3A-D). As expected, there
was good correlation among the number of countable merozoites and
DNA and hemozoin synthetic activities.
To further characterize the changes induced by Syk inhibition,
we measured the relative abundance of each parasite stage (rings,
trophozoites, schizonts) at different time points. In comparison
with untreated cultures, R406 (1 mM) treatment caused few
changes during the ﬁrst lifecycle. However, during the second
cycle of growth, R406 treatment resulted in a marked reduction in
ring-stage parasites and an accumulation of dead parasites
(Figure 4A-B). With still higher concentrations of Syk inhibitors,
anomalous schizont forms were also observed at the end of the ﬁrst
cycle (see above). The initial number of parasites was 150 000/mL
(12 hpi) in control and treated cultures. Parasitemia did not
signiﬁcantly change during the ﬁrst cycle. At the beginning of the
second cycle, the parasite number was 515 000/mL (60 hpi) in
control cells and 45 000/mL in treated cells. The number of viable
parasites remained constant in control cells along the second cycle
(84 hpi), whereas it dropped to zero in the treated ones. In a second
set of experiments,P falciparum synchronous cultures were treated
with different Syk inhibitors at variable concentrations. IC50 was
measured after 24 and 48 hours of treatment using 2 different
parasite strains and fresh isolates from malaria patients living in an
area of suspected artemisinin resistance in central Vietnam (Quang
Tri province) (Table 2).
In agreement with the delayed effect of Syk inhibitors, their
IC50 were much higher when measured during the ﬁrst cycle of
growth (24 hours after treatment) than at the second cycle (48
hours after treatment) (Table 2). The tested Syk inhibitors
revealed similar IC50, although R406 showed consistently lower
IC50. To further support the hypothesis that Syk inhibition
interferes with the parasite growth, suppressing the phosphory-
lation of band 3, we measured phosphorylated band 3 levels in
parallel to parasite growth inhibition at the different concentration
of R406 used to measure the IC50. Figure 5A shows a good
correlation between the inhibition of band 3 phosphorylation and parasite
growth suppression.
In a third set of experiments, we measured the stage dependency of
Syk inhibitors activity. Figure 5B shows that adding R406 (1.0
mM) at different stages of parasite development, the maximal
activity was observed between 12 and 36 hours postinfection
corresponding to ring and trophozoite stages. We also performed
experiments in which R406 was added 24 hours postinfection
and then washed out after 8 and 12 hours. Under those conditions,
R406 exhibited similar inhibitory effects on parasite growth as in
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Figure 4. Effect of Syk inhibitors on parasite stage differentia-
tion. Percentage of the different parasite stages (Stages %)
during the course of 2 growth cycles. R406 was added at
20 hours postinfection, measured in (A) control cells and
(B) R406 (1.0 mM) cells. The percentage of severely altered
parasites (dead parasites) is also shown. Data are means 6 SD.
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experiments where it was not removed from the cultures (data not
shown). This result indicates that a short-term inhibition of Syk at
the ring and trophozoite stages markedly affects the capability of
the parasite to complete its growth cycle. However, addition of R406
in the last 8 hours of parasite development (40 hours postinfection)
wasmuch less effective (Figure 4B).However, addition ofR406 in the
last 8 hours of parasite development (40 hours postinfection) was
much less effective (Figure 4B) and it may be due to the low amount
of residual Syk and band 3 observed at late parasite maturation stages
(see Figure 1C-D).
Discussion
The erythrocyte anion exchanger, band 3, constitutes the major
integral protein of the human erythrocyte membrane, where it
comprises ;25% of the total membrane protein. Band 3 serves
not only to catalyze exchange of anions across the membrane47,48
but also to nucleate a complex of glycolytic enzymes on the
membrane,49,50 provide a binding site for multiple kinases and
phosphatases,49 and anchor the spectrin-actin cytoskeleton to the
bilayer.51,52 Although all of these functions contribute critically to
RBC biology, its role in linking the cytoskeleton to the membrane
may be most critical, because rupture of either the band 3-ankyrin
or the band 3-adducin bridge to the spectrin-based membrane
skeleton leads tomembrane destabilization and fragmentation.53-55
Interestingly, Syk inhibitors do not apparently play a role in the
assembling of parasite proteins that ultimately lead to the formation
of knobs in the host cell membrane.56
Previous work has shown that phosphorylation of tyrosines 8
and 21 in the cytoplasmic domain of band 3 in fact causes
dissociation of ankyrin from band 3, resulting in rupture of the
major bridge linking band 3 to the cytoskeleton.31,39,57 Although
healthy RBCs show no obvious evidence of band 3 tyrosine
phosphorylation, P falciparum–infected RBCs display a gradual
increase in band 3 phosphorylation leading to the anticipated
membrane destabilization and vesiculation. Band 3 phosphoryla-
tion is very plausibly due to oxidative stress exerted by the parasite
growth because it is capable of activating the docking of Syk to
band 3 and to inhibit Tyr phosphatases.36,38 Because this process
eventually culminates in the rupture of the host cell membrane
and release of the newly developed merozoites into circulation,
we wondered whether selective inhibition of the tyrosine
phosphorylation of band 3 might inhibit the phosphorylation-
induced membrane destabilization sufﬁciently to prevent parasite
egress and thereby terminate parasitemia.
We have shown here that Syk tyrosine kinase inhibitors not only
prevent the tyrosine phosphorylation of band 3 inP falciparum pRBCs
but also reduce the subsequent release of membrane-derived MPs,
mitigate the loss of band3 andSyk from the infected cells, andblock the
egress of mature merozoites from the pRBCs. Because the impact of
Syk inhibitors on these parasite-mediated processes is proportional to
their inhibition of band 3 phosphorylation, we hypothesize that an
appropriately designed inhibitor of erythrocyte Syk might prevent
parasite egress and thereby constitute a treatment of P falciparum
malaria.
Although the above observations might be interpreted to imply that
the antimalarial properties of Syk inhibitors all derive from
blockade of band 3 tyrosine phosphorylation, closer scrutiny of
the data suggests that Syk kinase inhibitors suppress parasitemia
by more than a single mechanism. Thus, at low inhibitor con-
centrations (.twofold below IC50), tyrosine phosphorylation of
band 3 is reduced, loss of band 3 from the RBC membrane is
mitigated, and mature merozoite egress is suppressed. That the
entrapped parasites in such treated cells are neither dead nor
inactivated can be discerned from the observation that parasites
released from these RBCs by shear stress are fully capable of
invading uninfected RBCs and propagating the parasitemia. In
contrast, at higher Syk inhibitor concentrations, a decrease in
parasite DNA synthesis, hemozoin formation, and number of
merozoites per schizont all suggest that additional parasite
processes have been perturbed and that P falciparum viability
has been compromised.
Although we have emphasized the importance of tyrosine
phosphorylation on the mechanism of merozoite egress from
infected RBCs, it should be noted that the egress process is very
complex, involving multiple mechanisms, including activation of
proteases, phospholipases, and osmotic swelling.13,58-60 Indeed,
our current understanding of the relative contributions of each of
these mechanisms to parasite egress is too inadequate to allow
prediction of whether blockade of any single mechanismmight be
sufﬁcient to constitute a mutation-resistant therapy for malaria.
However, the fact that the P falciparum genome encodes no
classical protein tyrosine kinases61,62 suggests that mutations in a
parasite kinase that might compensate for an inhibited Syk kinase
should be difﬁcult to evolve. Syk inhibitors are currently
undergoing human clinical trials for treatment of autoimmune,
allergic, and neoplastic disorders.63-69 In the case of autoimmune
diseases, Syk inhibitors must be administered on a regular basis in
perpetuity, requiring that the therapy be very well tolerated. For
instance, R406 has demonstrated a good safety proﬁle in phase 3
clinical trials for the treatment of rheumatoid arthritis and
idiopathic thrombocytopenic purpura, and Imatinib, a bcr-abl
inhibitor with relatively potent action on Syk,70,71 has been
used for continuous treatment of chronic myeloid leukemia.72
Importantly, the IC50 values of both inhibitors for treatment of
malaria are within the plasma concentrations achieved following
oral administration for treatment of the above pathologies.73-75
Because Syk inhibitors have a relatively long half-life and act at
the end of the parasite cycle, they would be expected to gradually
decrease parasitemia and lead to symptomatic resolution. These
Table 2. IC50 values of the Syk inhibitors SYK II, SYK IV, and R406 in
2 different P falciparum laboratory strains (Palo Alto and Dd2) and
ex vivo grown isolates from Vietnamese malaria patients
24 h 48 h
Palo Alto strain
Syk inhibitors IC50 (mΜ) IC50 (mΜ)
SYK II 5.01 6 0.44 0.9 6 0.16
SYK IV 7.28 6 0.4 1.75 6 0.31
R406 2.62 6 0.83 0.55 6 0.19
Dd2 strain
Syk inhibitors IC50 (mΜ) IC50 (mΜ)
SYK II 4.62 6 0.44 0.68 6 0.15
SYK IV 6.39 6 0.46 1.28 6 0.28
R406 3.58 6 0.37 0.69 6 0.26
Ex vivo–grown isolates from Vietnam
SYK II (N 5 23) 4.48 6 0.37 0.71 6 0.9
R406 (N5 23) 3.02 6 0.23 0.44 6 0.4
Syk inhibitors were added to synchronized parasite cultures at 16 to 20 hours
postinvasion. The IC50 was determined after 24 and 48 hours incubation of the
treated cultures by counting the parasitemia during the 2 subsequent erythrocytic
cycles (40-44 and 64-68 hours after first invasion).
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characteristics may be an advantage if administered in associa-
tion with a fast-acting antimalarial drug such as an artemisinin
derivative, allowing for both a rapid and prolonged antiplasmodial
activity. In conclusion, considering their demonstrated tolerability,
Syk inhibitors may represent a new class of antimalarial drugs that
possess a unique mechanism of action on a nonparasite target,
should not lead to the selection of resistant strains, and may
therefore represent a strategic partner drug for counteracting
artemisinin resistance.
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Figure 5. Effect of Syk inhibitors on growth inhibition and
band 3 phosphorylation; stage-dependent sensitivity of
parasite to R406 treatment. (A) Parasite growth inhibition
(% growth inhibition) and the levels of band 3 phosphorylation
at different concentrations of R406 expressed as a percentage
of the band 3 maximal phosphorylation levels measured in un-
treated cultures (% phosphorylation). Parasitemia was measured
at the second cycle of growth, and band 3 phosphorylation was
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